Grail

Grail Liabilities

The The Liabilities of Grail (GRAL) as of Oct 20, 2026 is 344.15 M USD. In the previous year, The Liabilities was 479.90 M USD — a change of -28.29% (lower).

Liabilities

344.15 MUSD

YoY

-28.29%

Last updated:

In 2025, Grail's total liabilities amounted to 344.15 M USD, a -28.29% difference from the 479.90 M USD total liabilities in the previous year.

The Grail Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
86.47 M USD
Jan 1, 2019
84.99 M USD
Jan 1, 2020
144.46 M USD
Jan 1, 2021
307.40 M USD
Jan 1, 2022
955.94 M USD
Jan 1, 2023
910.74 M USD
Jan 1, 2024
479.90 M USD
Jan 1, 2025
344.15 M USD
The Grail Liabilities history
YEARLiabilitiesYoY
344.15 MUSD-28.29%
479.90 MUSD-47.31%
910.74 MUSD-4.73%
955.94 MUSD+210.98%
307.40 MUSD+112.79%
144.46 MUSD+69.97%
84.99 MUSD-1.71%
86.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc generates revenue through its Galleri and Beyond products, which are designed for multi-cancer early detection. Galleri is a commercially available screening test that identifies multiple cancer types in early stages using methylation-based technology, supporting healthcare providers in guiding diagnostic pathways. The company targets healthcare systems, hospitals, and insurance providers as key buyers, focusing on population-scale clinical studies and precision oncology applications. Its platform integrates next-generation sequencing, machine learning, and automation to address cancer detection across various care continuum segments. The business model centers on selling Galleri tests to healthcare institutions for use in patient screening programs, with Beyond serving as an additional product for precision oncology needs. Buyers include healthcare systems seeking to implement early cancer detection protocols and insurance companies aiming to reduce long-term treatment costs through early intervention. The company leverages its methylation-based platform to provide solutions for risk stratification, minimal residual disease detection, and treatment monitoring, aligning with the growing demand for advanced cancer screening technologies. Grail Inc's revenue streams are derived from the commercialization of Galleri, which is positioned as a multi-cancer early detection (MCED) tool, and Beyond, which supports specialized oncology applications. The company's target segments encompass healthcare providers, insurance partners, and research institutions involved in population-scale studies. By focusing on early detection and precision oncology, Grail Inc addresses unmet needs in cancer care through its technology-driven approach. Grail is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Grail's Liabilities

Grail's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Grail's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Grail's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Grail's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Grail’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Grail stock

The Liabilities of Grail is 344.15 M USD in 2025.

The Liabilities of Grail changed from 479.90 M USD to 344.15 M USD, representing a -28.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Grail since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Grail historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Grail

All Key Metrics — Grail